NASDAQ:OCUL - Ocular Therapeutix Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $24.80
  • Forecasted Upside: 58.57 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 1 Strong Buy Ratings
$15.64
▲ +0.35 (2.29%)
1 month | 3 months | 12 months
Get New Ocular Therapeutix Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OCUL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OCUL

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$24.80
▲ +58.57% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Ocular Therapeutix in the last 3 months. The average price target is $24.80, with a high forecast of $30.00 and a low forecast of $14.00. The average price target represents a 58.57% upside from the last price of $15.64.
Buy
The current consensus among 4 contributing investment analysts is to buy stock in Ocular Therapeutix. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 1 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/30/2019
  • 1 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/28/2020
  • 1 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/27/2020
  • 1 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/26/2020
  • 1 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/24/2020
  • 1 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/22/2021
  • 1 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/23/2021
  • 1 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/22/2021

Latest Recommendations

  • 1 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/30/2020JMP SecuritiesBoost Price Target$20.00 ➝ $30.00N/A
i
12/28/2020HC WainwrightDowngradeBuy ➝ NeutralN/A
i
Rating by Y. Chen at HC Wainwright
12/21/2020Piper SandlerBoost Price Target$16.00 ➝ $28.00Low
i
12/17/2020Berenberg BankInitiated CoverageBuy$27.00Medium
i
11/13/2020Raymond JamesBoost Price TargetStrong-Buy$15.00 ➝ $25.00High
i
11/6/2020HC WainwrightBoost Price TargetBuy$13.00 ➝ $14.00High
i
9/30/2020HC WainwrightReiterated RatingBuy$13.00High
i
8/10/2020HC WainwrightBoost Price TargetBuy$10.00 ➝ $13.00High
i
Rating by Yi Chen at HC Wainwright
7/22/2020Piper SandlerBoost Price TargetOverweight$11.00 ➝ $14.00Low
i
4/29/2020HC WainwrightReiterated RatingPositive ➝ Buy$8.00 ➝ $10.00High
i
Rating by Yi Chen at HC Wainwright
3/17/2020Jefferies Financial GroupInitiated CoverageBuy$8.00High
i
3/5/2020Piper SandlerReiterated RatingOverweight$7.00 ➝ $11.00High
i
3/4/2020HC WainwrightReiterated RatingBuy$8.00High
i
Rating by Yi Chen at HC Wainwright
3/3/2020Raymond JamesUpgradeOutperform ➝ Strong-BuyHigh
i
2/10/2020Piper SandlerBoost Price Target$5.50 ➝ $7.00Low
i
2/10/2020HC WainwrightReiterated RatingBuy ➝ Positive$6.00 ➝ $8.00Medium
i
Rating by Yi Chen at HC Wainwright
11/15/2019HC WainwrightReiterated RatingBuy$9.00 ➝ $6.00High
i
Rating by Yi Chen at HC Wainwright
11/12/2019Piper Jaffray CompaniesLower Price TargetOverweight$8.00 ➝ $5.00High
i
Rating by Joseph Catanzaro at Piper Jaffray Companies
10/18/2019HC WainwrightReiterated RatingBuy$9.00Low
i
Rating by Yi Chen at HC Wainwright
9/25/2019HC WainwrightReiterated RatingBuy$9.00High
i
Rating by Yi Chen at HC Wainwright
7/26/2019Piper Jaffray CompaniesSet Price TargetBuy$8.00N/A
i
Rating by Joseph Catanzaro at Piper Jaffray Companies
7/2/2019Piper Jaffray CompaniesSet Price TargetBuy$8.00Low
i
Rating by Joseph Catanzaro at Piper Jaffray Companies
7/2/2019HC WainwrightSet Price TargetBuy$9.00Low
i
Rating by Yi Chen at HC Wainwright
6/24/2019HC WainwrightReiterated RatingBuy$9.00High
i
Rating by Ram Selvaraju at HC Wainwright
6/21/2019JMP SecuritiesSet Price TargetBuy$9.00Low
i
Rating by Donald Ellis at JMP Securities
5/21/2019HC WainwrightLower Price TargetBuy$12.00 ➝ $9.00High
i
Rating by Ram Selvaraju at HC Wainwright
5/21/2019Raymond JamesDowngradeStrong-Buy ➝ Outperform$11.00 ➝ $5.00High
i
5/21/2019CowenDowngradeOutperform ➝ Market Perform$13.00 ➝ $3.00High
i
5/20/2019Piper Jaffray CompaniesLower Price TargetOverweight ➝ Market Perform$8.00High
i
Rating by Joseph Catanzaro at Piper Jaffray Companies
3/8/2019Piper Jaffray CompaniesSet Price TargetBuy$14.00Medium
i
Rating by Joseph Catanzaro at Piper Jaffray Companies
3/7/2019Cantor FitzgeraldReiterated RatingBuy$24.00Low
i
Rating by Elemer Piros at Cantor Fitzgerald
1/11/2019HC WainwrightSet Price TargetBuy$12.00Low
i
Rating by Ram Selvaraju at HC Wainwright
12/4/2018HC WainwrightReiterated RatingBuy$12.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
12/4/2018CowenReiterated RatingBuy$13.00Medium
i
12/3/2018Cantor FitzgeraldBoost Price TargetOverweight ➝ Overweight$22.00 ➝ $24.00High
i
Rating by Elemer Piros at Cantor Fitzgerald
11/14/2018Raymond JamesInitiated CoverageStrong-Buy ➝ Strong-Buy$10.00High
i
10/11/2018JMP SecuritiesReiterated RatingBuy$9.00High
i
Rating by Donald Ellis at JMP Securities
10/10/2018HC WainwrightSet Price TargetBuy$10.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
10/3/2018Cantor FitzgeraldSet Price TargetBuy$22.00Low
i
Rating by Elemer Piros at Cantor Fitzgerald
9/6/2018Piper Jaffray CompaniesInitiated CoverageOverweight ➝ OverweightLow
i
8/20/2018JMP SecuritiesSet Price TargetBuy$9.00Low
i
Rating by Donald Ellis at JMP Securities
8/8/2018HC WainwrightSet Price TargetBuy$10.00High
i
Rating by Ram Selvaraju at HC Wainwright
8/7/2018Cantor FitzgeraldSet Price TargetBuy$22.00High
i
Rating by Elemer Piros at Cantor Fitzgerald
7/20/2018HC WainwrightSet Price TargetBuy$10.00High
i
Rating by Ram Selvaraju at HC Wainwright
7/19/2018Cantor FitzgeraldSet Price TargetBuy$22.00High
i
Rating by Elemer Piros at Cantor Fitzgerald
7/2/2018HC WainwrightSet Price TargetBuy$10.00Low
i
Rating by Ram Selvaraju at HC Wainwright
6/21/2018HC WainwrightReiterated RatingBuy$10.00High
i
Rating by Ram Selvaraju at HC Wainwright
5/9/2018HC WainwrightSet Price TargetBuy$10.00High
i
Rating by Ram Selvaraju at HC Wainwright
5/8/2018Cantor FitzgeraldSet Price TargetBuy$22.00High
i
Rating by Elemer Piros at Cantor Fitzgerald
3/11/2018BTIG ResearchReiterated RatingBuyHigh
i
3/9/2018HC WainwrightReiterated RatingBuy$10.00Low
i
Rating by R. Selvaraju at HC Wainwright
3/8/2018Cantor FitzgeraldReiterated RatingBuy$22.00Low
i
Rating by Elemer Piros at Cantor Fitzgerald
1/19/2018BTIG ResearchUpgradeNeutral ➝ BuyHigh
i
11/8/2017HC WainwrightReiterated RatingBuy$10.00N/A
i
Rating by Ram Selvaraju at HC Wainwright
10/23/2017GuggenheimInitiated CoverageBuy$12.00N/A
i
9/25/2017Cantor FitzgeraldReiterated RatingBuy$21.00Low
i
Rating by Elemer Piros at Cantor Fitzgerald
8/10/2017BTIG ResearchReiterated RatingNeutralLow
i
8/9/2017HC WainwrightReiterated RatingBuy$10.00High
i
Rating by Ram Selvaraju at HC Wainwright
8/2/2017HC WainwrightSet Price TargetBuy$10.00High
i
Rating by Ram Selvaraju at HC Wainwright
7/26/2017HC WainwrightInitiated CoverageBuy ➝ Buy$10.00Low
i
7/17/2017BTIG ResearchReiterated RatingNeutralLow
i
7/14/2017Morgan StanleyReiterated RatingEqual Weight$16.00 ➝ $8.00Low
i
7/12/2017Cantor FitzgeraldLower Price TargetOverweight ➝ Overweight$35.00 ➝ $21.00High
i
Rating by Elemer Piros at Cantor Fitzgerald
7/10/2017Cantor FitzgeraldSet Price TargetBuy$35.00Medium
i
Rating by Elemer Piros at Cantor Fitzgerald
6/23/2017Morgan StanleyDowngradeOverweight ➝ Equal Weight$16.00High
i
5/15/2017Cantor FitzgeraldReiterated RatingOverweight$35.00Low
i
Rating by E. Piros at Cantor Fitzgerald
5/15/2017BTIG ResearchDowngradeBuy ➝ NeutralLow
i
5/5/2017Cantor FitzgeraldReiterated RatingOverweight$35.00Low
i
Rating by E. Piros at Cantor Fitzgerald
5/5/2017BTIG ResearchDowngradeBuy ➝ NeutralMedium
i
3/21/2017Cantor FitzgeraldReiterated RatingOverweightLow
i
Rating by E. Piros at Cantor Fitzgerald
3/21/2017BTIG ResearchReiterated RatingBuy$13.00Low
i
Rating by Ling Wang at BTIG Research
3/13/2017CowenReiterated RatingOutperform$60.00Medium
i
3/11/2017Cantor FitzgeraldSet Price TargetBuy$35.00Medium
i
Rating by Elemer Piros at Cantor Fitzgerald
2/9/2017Cantor FitzgeraldInitiated CoverageOverweight$35.00N/A
i
1/24/2017BTIG ResearchReiterated RatingBuy$13.00N/A
i
Rating by Ling Wang at BTIG Research
11/15/2016Royal Bank of CanadaReiterated RatingOutperform$30.00 ➝ $32.00N/A
i
11/15/2016Royal Bank of CanadaBoost Price TargetOutperform$30.00 ➝ $32.00N/A
i
10/23/2016BTIG ResearchReiterated RatingBuy$18.00N/A
i
Rating by Ling Wang at BTIG Research
10/15/2016BTIG ResearchReiterated RatingBuy$18.00N/A
i
8/11/2016JMP SecuritiesInitiated CoverageOutperform$21.00 ➝ $5.84N/A
i
7/26/2016BTIG ResearchReiterated RatingBuy$18.00N/A
i
6/7/2016Morgan StanleyReiterated RatingOverweight$17.00 ➝ $16.00N/A
i
Rating by Andrew Berens at Morgan Stanley
6/6/2016CowenReiterated RatingBuyN/A
i
Rating by Tyler Van Buren at Cowen Inc
5/12/2016Morgan StanleyReiterated RatingBuyN/A
i
Rating by Andrew Berens at Morgan Stanley
4/28/2016Morgan StanleyBoost Price TargetOverweight$15.00 ➝ $17.00N/A
i
Rating by Andrew Berens at Morgan Stanley
(Data available from 4/22/2016 forward)
Ocular Therapeutix logo
Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.
Read More

Today's Range

Now: $15.64
$15.11
$15.72

50 Day Range

MA: $17.88
$14.78
$20.84

52 Week Range

Now: $15.64
$4.76
$24.30

Volume

4,004 shs

Average Volume

930,798 shs

Market Capitalization

$1.19 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.29

Frequently Asked Questions

What sell-side analysts currently cover shares of Ocular Therapeutix?

The following Wall Street sell-side analysts have issued stock ratings on Ocular Therapeutix in the last year: Berenberg Bank, HC Wainwright, JMP Securities, Piper Sandler, Raymond James, and Zacks Investment Research.
View the latest analyst ratings for OCUL.

What is the current price target for Ocular Therapeutix?

5 Wall Street analysts have set twelve-month price targets for Ocular Therapeutix in the last year. Their average twelve-month price target is $24.80, suggesting a possible upside of 62.2%. JMP Securities has the highest price target set, predicting OCUL will reach $30.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $14.00 for Ocular Therapeutix in the next year.
View the latest price targets for OCUL.

What is the current consensus analyst rating for Ocular Therapeutix?

Ocular Therapeutix currently has 1 hold rating, 2 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe OCUL will outperform the market and that investors should add to their positions of Ocular Therapeutix.
View the latest ratings for OCUL.

What other companies compete with Ocular Therapeutix?

How do I contact Ocular Therapeutix's investor relations team?

Ocular Therapeutix's physical mailing address is 15 CROSBY DRIVE, BEDFORD MA, 01730. The biopharmaceutical company's listed phone number is (781) 357-4000 and its investor relations email address is [email protected] The official website for Ocular Therapeutix is www.ocutx.com.